Supplementary Material and Methods

Plasmids

pOM168 was constructed by cloning a PCR fragment containing the sequence encoding residues 102-753 of *PH0952* amplified from the *Pyrococcus horikoshii* OT3 chromosome between the Xbal and Kpnl sites of pKYB1, so as to yield the following sequence between these two sites.

XbaI NCOI KpnI <u>TCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGG</u>CCCCT-*PH0952*-AACTTTAAGTGCTTTGCCAAG<u>GGTACC</u> M A PN F K C F A K G T 102 753 1 2 3 4 5 6 < *PH0952* sequence >< Sce VMA1 intein gene sequence

pOM258 is a derivative of pOM257 (16): like this plasmid it contains a $P_{KAB-TTGG}$ -malT fragment cloned between the EcoRI and BamHI sites of pJM241, but without the silent SacI site at +21 of the malT sequence and with a KpnI silent site at +2478.

pOM260 is a derivative of pOM215 (60) which contains a $P_{KAB-TTCT}$ -*malT* fragment cloned between the EcoRI and BamHI sites of pJM241 without the SacI silent site at 2381 but with a KpnI silent site at +2478 which makes the sequence of the *malT* gene identical to that of pOM258.

Growth media

Growth media for purification of PH0952 Δ N and selenomethionine substituted PH0952 Δ N contained 100 µg/mL kanamycine and 10 µg/mL chloramphenicol.

The medium used for production of the selenomethionine substituted PH0952 Δ N contained 50 mM Na₂HPO₄, 50mM KH₂PO₄, 25 mM (NH₄)₂SO₄, 2 mM MgSO₄, 0.2x trace metals (19), 0.5% glucose, 10 µg/mL L-methionine, 100 µg/mL L-selenomethionine, 1.5 mM of 17 amino-acids (no C, M, Y), 100 nM vitamin B12 and 1 mM IPTG.



Figure S1: Maximum likelihood phylogenetic analysis of STAND ATPases. The tree contains representative members from different families of STAND proteins. Numbers at the branch points represent the Bayesian-like transformation of aLRT (aBayes) local support values. The scale bar represents the number of substitutions per site. The tree is rooted in the branch leading to the MNS clade (1). Searches against expanded genomic databases indicate that PH0952-like ATPases are more broadly distributed in archaeal lineages than anticipated, particularly in Euryarchaeota, but also in members of the phylum Crenarchaeota and various recently discovered uncultivated archaea. Contrary to previous hypotheses of a horizontal transfer of *PH0952* into archaea from bacteria or eukaryotes (1,38), our analysis (see also Fig. 1C) suggests that PH0952-like ATPases, but rather represent a distinct family within the STAND superfamily.



Figure S2: The ADP binding site of PH0952. The protein is shown in cartoon representation and the ADP molecule is depicted in sticks. The original SAD-phased, density modified electron density map (blue mesh) is contoured at 1.5σ .



Figure S3: Interactions between consecutive domains in the NOD-arm module of STAND proteins. The NOD-arm regions of PH0952/APAF1 (left) and NLRC4/NOD2 (right) were superimposed through their P-loop regions and put side by side in the same orientation, in two perpendicular views (top and bottom). Relevant secondary structure elements are indicated, either once when the superimposition is good, or twice when the two structures do not overlap.



Fig. S4 : Secondary structure of the PH0952 derived from the atomic coordinates determined in this work. The colour code for domains is as in Fig. 1. The dashed line indicates the unresolved region between the HD and the WHD.

No:	Chain	Z	rmsd	lali	nres	%id PDB	Descriptio	n
<u>1</u> :	3q78-A	7.3	3.2	90	312	10 <u>PDB</u>	MOLECULE:	FARNESYLTRANSFERASE ALPHA SUBUNIT;
<u>2</u> :	<u>5jz6-A</u>	7.2	3.4	89	429	15 <u>PDB</u>	MOLECULE:	ASPARTYL/ASPARAGINYL BETA-HYDROXYLASE;
<u>3</u> :	<u>5jjt-B</u>	7.2	3.1	90	479	7 <u>PDB</u>	MOLECULE:	SERINE/THREONINE-PROTEIN PHOSPHATASE 5;
<u>4</u> :	<u>3sfy-A</u>	7.1	3.2	90	315	10 <u>PDB</u>	MOLECULE:	CRYPTOCOCCUS NEOFORMANS PROTEIN FARNESYLTRANSFERA
<u>5</u> :	3q79-A	7.1	3.3	90	314	10 <u>PDB</u>	MOLECULE:	FARNESYLTRANSFERASE ALPHA SUBUNIT;
6:	3q75-A	7.1	3.2	90	315	10 <u>PDB</u>	MOLECULE:	FARNESYLTRANSFERASE ALPHA SUBUNIT;
<u>7</u> :	<u>ln4s-C</u>	7.1	3.1	89	314	11 <u>PDB</u>	MOLECULE:	PROTEIN FARNESYLTRANSFERASE/GERANYLGERANYLTRANSFE
<u>8</u> :	<u>3q73-A</u>	7.1	3.3	90	316	10 <u>PDB</u>	MOLECULE:	FARNESYLTRANSFERASE, ALPHA SUBUNIT;
9:	3q7f-A	7.1	3.3	90	313	10 <u>PDB</u>	MOLECULE:	FARNESYLTRANSFERASE ALPHA SUBUNIT;
<u>10</u> :	5jjt-A	7.0	3.1	88	471	7 <u>PDB</u>	MOLECULE:	SERINE/THREONINE-PROTEIN PHOSPHATASE 5;

Fig. S5 : First 10 structural homologs found by a Dali search (october 24, 2017) seeded with the coordinates of the PH0952 arm. Headers in red indicate TPR proteins. The other proteins retrieved have a farnesyl-transferase α -subunit fold, which differs from TPR repeats essentially by the twist (i.e. the way consecutive two-helix bundles are spatially related to each other, (44))



Fig. S6: Comparison of the 4 STAND arm domains for which a crystal structure is available. Helices are rainbow colored from blue (first helix) to red (6th helix). Possible insertions are represented in grey.

А





Fig. S7: A. Schematic representation of a typical TPR fold wiewed along the helix longitudinal axis (helices are represented by circles and turns by dashes). ABA (red) and BAB (blue) angles are shown. B,C. Superimposition of groups of three consecutive helices from the arm (α 15 to α 20) and as a comparison, from the TPR sensor domain of PH0952 (α 21 to α 24). B. ABA angles. C. BAB angles.



Fig. S8: Opposite charge complementarities in the MalT homology model (top) and in the PH0952 X-ray structure (bottom). Electrostatic potential surfaces are shown after splitting the structure in two at the arm sensor junction. The PH0952 sensor-NBD interface patches are contoured and a representative residue is indicated.



Fig. S9: The cysteine mutations do not affect MalT activation. MalT^{M96C}, MalT^{H562C} and MalT^{M96C-H562C} display inducer dependent multimerization as MalT in reducing conditions. Proteins (10 μ M) were preincubated for 30 min in a Tris-HCl buffer (50 mM, pH 8.0) containing 10% sucrose, 0.1 M KCl, 0.033 M Kl, 0.017 mM K₃ citrate,10 mM Mg acetate, 0.1 mM EDTA, 2 mM dithiothreitol, 0.18 mM ATP. They were injected on a superdex 200 column equilibrated with a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM G acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K₃ citrate, 10 mM Mg acetate, 0.1 mM et a Tris-HCl buffer (50 mM, pH 8.0) containing 0.033 M K mg acetate (50 mM, pH 8.0) containing 0.033 M K mg acetate (50 mM, pH 8.0) containing 0.033 M K mg acetate (50 mM, pH 8.0) containing 0.033 M K mg acetate (50 mM, pH 8.0) containing 0.033 M K mg acetate (50 mM, pH 8.0) containing 0.033 M K mg acetate (50



Fig. S10: MalT, MalT^{M96C}, MalT^{H562C} and MalT^{M96C-H562C} all migrate at the same level in the presence of DTT. The gel used to generate Fig. 5a is shown in its entirety to enable comparison of the migrations of the four different proteins in reducing conditions. +DTT lanes are highlighted for clarity. 1, 2 : MalT, 3: MalT^{M96C}, 4: MalT^{H562C}, 5: MalT^{M96C,H562C}. Molecular weights of the markers are indicated in kDa.



Fig. S11: The *M96T* mutation does not interfere with the maltotriose-induced conformational changes undergone by MalT or MalT^{R171E}. Limited proteolysis of MalT and variants by proteinase K in ADP and ATP + maltotriose. The same increasing K/MalT (w/w) ratios (0, 1:533, 1:267, 1:133) were used for all eight experiments. Green arrows point at the 50 kDa and 45-48 kDa fragments specific of the resting form. Red arrows points at the 66 kDa and 25 kDa fragments specific of the activated form. A. MalT, MalT^{M96T}. B. MalT^{R171E}, MalT^{M96T,R171E}.



Fig. S12: Calibration curves for the columns used in the experiments of Fig. 6A (open circles) and in those of Fig. 6B (closed circles). Markers (thyroglobulin, 669 kDa, apoferritin, 443 kDa, amylase, 200kDa, bovine serum albumin, 66 kDa, cytochrome C, 12.4 kDa) were injected on the columns equilibrated in Tris-HCl buffer (50 mM, pH 8.0) containing 10% sucrose, 0.033 M K3 citrate, 10 mM Mg acetate, 0.1 mM EDTA, 1 mM dithiothreitol and 0.1 mM ADP. Monomeric MaIT-ADP run at 10 μ M on the Fig. 6B column eluted at 1.484 mL. Theoretical elution volumes for a globular protein of the same molecular weight as MaIT calculated from the calibration curves are 1.40 mL (Fig. 6A column) and 1.47 mL (Fig. 6B column).